IP Library Granted Patent US 6,908,630
Granted Patent B2
US 6,908,630 · App. 09/919,349 · Granted Jun 21, 2005

Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,908,630
App. No.
09/919,349
Granted
Jun 21, 2005
Kind
B2
Abstract

A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component of a sesquiterpene lactone species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Claims (25)

1. A composition for inhibition of inducible cyclooxygenase-2 (COX-2) activity, said composition comprising as a first component an effective amount of a diterpene triepoxide lactone species, and as a second component an effective amount of a sesquiterpene lactone species, wherein the ratio of diterpene triepoxide lactone species to sesquiterpene lactone species is between 100:1 and 1:100.

2. The composition of claim 1 wherein the first and second components are derived from plants or plant extracts.

3. The composition of claim 1 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

4. The composition of claim 1 , formulated in a pharmaceutically acceptable carrier.

5. The composition of claim 1 , additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

6. A composition for inhibition of inducible cyclooxygenase-2 (COX-2) activity, said composition comprising as a first component an effective amount of pharmaceutical grade compound selected from the group consisting of triptolide, triptonide, tripdiolide and tripchlorolide, and as a second component an effective amount of parthenolide, encelin, leucanthin B, enhydrin, melanomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, helenalin, 5-α-hydroxy-dehydrocostuslactone, chlorochrymorin, chrysandiol, chrysartemin A, chrysartemin B, cinerenin, curcolone, cynaropicrin, dehydrocostus lactone, dehydroleucodin, dehydrozaluzanin C, deoxylatucin, eremanthine, eupaformonin, eupaformosanin, eupatolide, furanodienone, heterogorgiolide, lactucin, magnolialide, michelenolide, repin, spirafolide, and zaluzanin C.

7. The composition of claim 6 wherein the first and second components are derived from plants or plant extracts.

8. The composition of claim 6 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

9. The composition of claim 6 , formulated in a pharmaceutically acceptable carrier.

10. The composition of claim 6 , additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

11. A composition for inhibition of inducible cyclooxygenase-2 (COX-2) activity, said composition comprising as a first component an effective amount of pharmaceutical grade triptolide or triptonide, and as a second component an effective amount of a compound selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapodin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol and helenalin.

12. The composition of claim 11 wherein the first and second components are derived from plants or plant extracts.

13. The composition of claim 11 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

14. The composition of claim 11 , formulated in a pharmaceutically acceptable carrier.

15. The composition of claim 11 , additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

16. A composition for inhibition of inducible cyclooxygenase-2 (COX-2) activity, said composition comprising as a first component an effective amount of pharmaceutical grade triptolide and as a second component an effective amount of a compound selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapomdin A.

17. The composition of claim 16 wherein the first and second components are derived from plants or plant extracts.

18. The composition of claim 16 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

19. The composition of claim 16 , formulated in a pharmaceutically acceptable carrier.

20. The composition of claim 16 , additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

21. A composition for inhibition of inducible cyclooxygenase-2 (COX-2) activity, said composition comprising as a first component an effective amount of pharmaceutical grade triptolide and as a second component an effective amount of pharmaceutical grade parthenolide.

22. The composition of claim 21 wherein the first and second components are derived from plants or plant extracts.

23. The composition of claim 21 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and gluthathione.

24. The composition of claim 21 , formulated in a pharmaceutically acceptahle carrier.

25. The composition of claim 21 , additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →
CONFIRMATION OF ASSIGNMENT OF PATENT APPLICATIONS FROM ASHNI NATURACEUTICALS, INC. TO METAPROTEOMICS, LLC Recorded Nov 7, 2002
From: ASHNI NATURACEUTICALS, INC.
To: METAPROTEOMICS, LLC
Reel/Frame 013453/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2002
From: BABISH, JOHN G.; HOWELL, TERRENCE; PACIORETTY, LINDA
To: ASHNI NATURACEUTICALS, INC.
Reel/Frame 012429/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2002
From: BABISH, JOHN G.; HOWELL, TERRENCE; PACIORETTY, LINDA
To: ASHINI NATURACEUTICALS, INC.
Reel/Frame 012431/0401 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2002
From: BABISH, JOHN G.; HOWELL, TERRENCE; PACIORETTY, LINDA
To: ASHNI NATURACEUTICALS, INC.
Reel/Frame 012431/0405 →